Your browser is no longer supported. Please, upgrade your browser.
Settings
ATHX Athersys, Inc. daily Stock Chart
ATHX [NASD]
Athersys, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own2.00% Shs Outstand154.31M Perf Week3.89%
Market Cap288.56M Forward P/E- EPS next Y-0.33 Insider Trans-1.91% Shs Float135.11M Perf Month30.77%
Income-27.10M PEG- EPS next Q-0.08 Inst Own22.40% Short Float8.53% Perf Quarter26.35%
Sales24.70M P/S11.68 EPS this Y38.20% Inst Trans0.19% Short Ratio16.47 Perf Half Y-1.06%
Book/sh0.25 P/B7.48 EPS next Y5.90% ROA-41.70% Target Price7.67 Perf Year-23.67%
Cash/sh0.33 P/C5.66 EPS next 5Y28.00% ROE-58.10% 52W Range1.35 - 3.09 Perf YTD29.86%
Dividend- P/FCF- EPS past 5Y19.70% ROI-58.10% 52W High-39.48% Beta0.26
Dividend %- Quick Ratio3.10 Sales past 5Y58.40% Gross Margin- 52W Low38.52% ATR0.13
Employees75 Current Ratio3.10 Sales Q/Q27.30% Oper. Margin- RSI (14)61.54 Volatility8.00% 8.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.90% Profit Margin- Rel Volume0.83 Prev Close1.86
ShortableYes LT Debt/Eq0.00 EarningsMay 08 AMC Payout- Avg Volume700.05K Price1.87
Recom1.70 SMA2011.68% SMA5019.24% SMA2006.79% Volume584,183 Change0.54%
Feb-13-18Reiterated Maxim Group Buy $12 → $6
Aug-10-17Reiterated Maxim Group Buy $9 → $12
Feb-07-17Initiated Needham Buy $7
Mar-11-16Reiterated Maxim Group Buy $5 → $10
Jul-09-15Downgrade Piper Jaffray Overweight → Neutral
Jan-23-15Reiterated Maxim Group Buy $7 → $9
Apr-28-14Reiterated Maxim Group Buy $10 → $7
Dec-19-13Reiterated Maxim Group Buy $6 → $10
Oct-05-12Reiterated Maxim Group Buy $3 → $6
May-31-12Initiated Maxim Group Buy $3
Sep-13-10Reiterated WBB Securities Strong Buy $8 → $9
Jul-30-10Upgrade WBB Securities Buy → Strong Buy $8
Apr-12-10Initiated Brean Murray Buy $8
Nov-11-08Reiterated Leerink Swann Outperform $8 → $4
Sep-17-08Initiated Leerink Swann Outperform $8
Aug-01-08Initiated Canaccord Adams Buy $6
Jun-19-08Initiated Lazard Capital Buy $7
Jun-02-08Initiated Cowen & Co Outperform
May-20-19 12:15PM  Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference GlobeNewswire -5.58%
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-14-19 03:54PM  Here's Why Athersys Rose as Much as 15.2% Today Motley Fool +13.92%
May-13-19 02:35AM  Edited Transcript of ATHX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 11:23AM  Athersys (ATHX) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 04:05PM  Athersys Reports First Quarter 2019 Results GlobeNewswire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Apr-23-19 04:08PM  Here's Why Athersys Is Soaring Today Motley Fool +16.08%
09:00AM  Athersys (ATHX) Upgraded to Strong Buy: Here's What You Should Know Zacks
06:00AM  HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of MultiStem® Treatment for Acute Respiratory Distress Syndrome GlobeNewswire
Apr-15-19 10:00AM  Athersys to Host Investor Day in New York City GlobeNewswire
Apr-10-19 02:00PM  Athersys to Host First Quarter Financial Results Call GlobeNewswire
Mar-20-19 08:08AM  Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 12:03PM  What Makes Athersys (ATHX) a New Buy Stock Zacks
Mar-14-19 07:16PM  Athersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:04PM  Athersys Announces Financial Results for Fourth Quarter and Full Year 2018 GlobeNewswire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-19 08:57AM  Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
Feb-27-19 11:04AM  Is Athersys, Inc.s (NASDAQ:ATHX) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-14-19 08:00AM  Athersys to Host Year-End 2018 Financial Results Call GlobeNewswire
Jan-24-19 02:20PM  Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study Zacks
Jan-23-19 09:27AM  Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock? Zacks +14.39%
06:00AM  Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS) GlobeNewswire
Dec-17-18 06:00AM  Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China GlobeNewswire -10.42%
Dec-03-18 12:18PM  Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-18 12:29PM  Are Athersys Incs (NASDAQ:ATHX) Interest Costs Too High? Simply Wall St.
Nov-06-18 04:05PM  Athersys Reports Third Quarter 2018 Results GlobeNewswire
Oct-29-18 08:45AM  Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-09-18 04:00PM  Athersys to Host Third Quarter Financial Results Call GlobeNewswire
Oct-08-18 10:07AM  Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7% Zacks
Oct-04-18 03:18PM  Alnylam Files Clinical Trial Application for ALN-AAT02 in UK Zacks
Oct-03-18 11:59AM  Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo Zacks
Oct-02-18 10:30AM  Global Stem Cell Market Expected to Reach $270.5 Billion ACCESSWIRE
Sep-24-18 06:00AM  Athersys to Present at 2018 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-20-18 11:14AM  Who Are The Major Shareholders Of Athersys Inc (NASDAQ:ATHX)? Simply Wall St.
Sep-14-18 09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
Aug-21-18 09:50PM  Edited Transcript of ATHX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 09:30AM  Is Athersys (ATHX) Stock Outpacing Its Medical Peers This Year? Zacks
Aug-14-18 07:30AM  Recent Analysis Shows Williams Partners, GameStop, Opko Health, Athersys, CSX, and Kratos Defense & Security Solutions Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-07-18 04:05PM  Athersys Reports Second Quarter 2018 Results GlobeNewswire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 06:00AM  Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy GlobeNewswire
Jul-31-18 06:00AM  Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke GlobeNewswire +6.38%
Jul-12-18 10:30AM  Biotechnology Companies Involved in Regenerative Medicine ACCESSWIRE
Jul-10-18 04:00PM  Athersys to Host Second Quarter Financial Results Call GlobeNewswire
Jun-29-18 09:11AM  4 Biotech Stocks to Bet on in the Second Half of 2018 Zacks
Jun-22-18 07:26AM  Athersys Enters Oversold Territory Zacks
Jun-13-18 07:05AM  Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities ACCESSWIRE
Jun-07-18 08:41AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:00AM  Athersys Announces Expansion of Collaboration With Healios GlobeNewswire
02:01AM  Athersys Announces Expansion of Collaboration With Healios GlobeNewswire
Jun-06-18 04:07PM  Edited Transcript of ATHX earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents
Jun-04-18 09:41AM  The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals Zacks +7.54%
Jun-01-18 08:42AM  "Right To Try" Brings Good News for Biotech Sector: 5 Picks Zacks
May-31-18 11:23AM  5 Biotech Stocks to Boost Your Portfolios Health This Year InvestorPlace
08:04AM  5 Biotech Stocks to Boost Your Portfolio's Health This Year Zacks
May-25-18 10:57AM  BioMarin's Palynziq Gets FDA Approval for Phenylketonuria Zacks
May-23-18 10:22AM  INSYS Gets Negative FDA Recommendation for Pain Candidate Zacks
May-22-18 07:24AM  Moving Average Crossover Alert: Athersys, Inc. (ATHX) Zacks
May-10-18 04:03PM  Athersys Reports First Quarter 2018 Results GlobeNewswire
12:11PM  Athersys Inc (NASDAQ:ATHX): Should The Recent Earnings Drop Worry You? Simply Wall St.
May-01-18 06:00AM  Athersys and Healios Extend by One Month the Period to Complete Collaboration Expansion Agreements GlobeNewswire
Apr-27-18 09:45AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Athersys, Inc. -- ATHX Business Wire
Apr-25-18 07:50AM  Recent Analysis Shows First Cash, ADTRAN, OMNOVA Solutions, Athersys, Oppenheimer, and Conn's Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-23-18 06:00AM  UTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem® to Treat Trauma Patients GlobeNewswire
Apr-12-18 04:00PM  Athersys to Host First Quarter Financial Results Call GlobeNewswire
Apr-11-18 02:56AM  Edited Transcript of ATHX conference call or presentation 28-Jul-10 8:30pm GMT Thomson Reuters StreetEvents
Mar-30-18 12:02PM  Best Growth Stock in March Simply Wall St.
Mar-26-18 07:10AM  Wired News Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT Trial ACCESSWIRE
Mar-20-18 01:00PM  Athersys to Present at Needham Healthcare Conference on March 28 GlobeNewswire
Mar-14-18 11:16AM  Edited Transcript of ATHX earnings conference call or presentation 13-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-13-18 04:05PM  Athersys Reports Financial Results for Fourth Quarter, Full Year 2017 GlobeNewswire +17.95%
12:15PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
08:12AM  Benzinga Pro's 5 Stock To Watch Today Benzinga
06:00AM  Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration GlobeNewswire
02:31AM  Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem® Collaboration GlobeNewswire
Mar-01-18 07:40AM  Report: Exploring Fundamental Drivers Behind BWX Technologies, WMIH, Conn's, Athersys, Proofpoint, and Kindred Healthcare New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-12-18 01:30PM  Athersys to Host Year-End 2017 Financial Results Call GlobeNewswire
Feb-02-18 06:00AM  Athersys Enters Into New $100 Million Equity Facility with Aspire Capital GlobeNewswire
Jan-29-18 06:00AM  Athersys CEO to Speak at the 2018 Brain Health Summit GlobeNewswire
Jan-04-18 08:15AM  Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-18-17 07:00AM  Tiny stem cell companies close in on major heart disease goals Reuters +7.19%
01:17AM  Tiny stem cell companies close in on major heart disease goals Reuters
01:00AM  Tiny stem cell companies close in on major heart disease goals Reuters
Nov-15-17 10:05AM  HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic Stroke GlobeNewswire
Nov-14-17 09:02AM  Edited Transcript of ATHX earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 04:03PM  Athersys Reports Third Quarter 2017 Results GlobeNewswire
01:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Oct-13-17 07:40AM  Featured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in Japan ACCESSWIRE
Oct-12-17 08:45AM  Athersys (ATHX) in Focus: Stock Moves 7.2% Higher Zacks -5.86%
08:00AM  Today's Research Reports on Trending Tickers: Athersys and Pluristem Therapeutics ACCESSWIRE
Oct-11-17 06:00AM  Athersys and Nikon CeLL Innovation to Collaborate on MultiStem® Commercial Manufacturing in Japan GlobeNewswire +7.17%
Oct-09-17 10:00AM  Athersys to Host Third Quarter Financial Results Call GlobeNewswire
Oct-05-17 07:00AM  Athersys to Present at 2017 Cell & Gene Meeting on the Mesa and Announces Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA GlobeNewswire +14.49%
Sep-07-17 08:38AM  Athersys (ATHX) in Focus: Stock Moves 10.22% Higher Zacks
08:00AM  Today's Research Reports on Trending Tickers: Athersys and Catalyst Biosciences ACCESSWIRE
Aug-13-17 09:36PM  Edited Transcript of ATHX earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 04:05PM  Athersys Reports Second Quarter 2017 Results GlobeNewswire
12:10PM  Investor Network: Athersys, Inc. to Host Earnings Call ACCESSWIRE
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lehmann William JRPresident and COOMar 18Sale1.5315,00022,947453,751Mar 18 05:13 PM
Harrington John JExec Vice Pres and CSOMar 15Sale1.547,50011,550628,718Mar 18 10:30 AM
Harrington John JExec Vice Pres and CSOMar 14Sale1.577,50011,738636,218Mar 18 10:30 AM
Lehmann William JRPresident and COODec 18Sale1.7315,00025,911478,062Dec 18 05:44 PM
Harrington John JExec Vice Pres and CSODec 14Sale1.867,50013,963652,770Dec 17 06:00 PM
Harrington John JExec Vice Pres and CSODec 13Sale2.007,50015,017660,270Dec 17 06:00 PM
Lehmann William JRPresident and COOSep 18Sale1.8815,00028,200502,373Sep 18 05:39 PM
Harrington John JExec Vice Pres and CSOSep 14Sale1.917,50014,359676,820Sep 17 05:05 PM
Harrington John JExec Vice Pres and CSOSep 13Sale1.917,50014,348684,320Sep 17 05:05 PM
Campbell Laura KSenior Vice Pres FinanceAug 10Sale2.0125,06850,367564,356Aug 10 06:40 PM
Campbell Laura KSenior Vice Pres FinanceAug 09Sale2.001,0002,000589,424Aug 10 06:40 PM
Campbell Laura KSenior Vice Pres FinanceAug 08Sale2.012,8005,619590,424Aug 10 06:40 PM
Campbell Laura KSenior Vice Pres FinanceAug 02Sale2.019,72019,491593,224Aug 03 07:16 PM
Campbell Laura KSenior Vice Pres FinanceAug 01Sale2.004,7009,423602,944Aug 03 07:16 PM
Lehmann William JRPresident and COOJun 19Sale2.2530,00067,380526,684Jun 19 05:49 PM
Harrington John JExec Vice Pres and CSOJun 15Sale2.307,50017,219597,320Jun 18 07:00 PM
Harrington John JExec Vice Pres and CSOJun 14Sale2.317,50017,294612,503Jun 18 07:00 PM